Subject:
- Active Substance: Maralixibat
- Name: Livmarli®
- Therapeutic area: Cholestatic pruritus
- Pharmaceutical company: Mirum Pharmaceuticals Germany GmbH
Time table:
- Start: 15.01.2023
- Final decision by G-BA: 06.07.2023
Final decision:
- Hint for a non-quantifiable additional benefit